Sign Out
Chemotherapy induced neutropenia: NEUTROMAX is indicated in patients with non-myeloid malignancy treated with established cytotoxic chemotherapy as it reduces the duration of neutropenia and the incidence of febrile neutropenia.
Patients receiving myeloablative chemotherapy followed by bone marrow transplantation: NEUTROMAX is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae in patients with non-myeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation.
Peripheral blood progenitor cell mobilization (PBPC): NEUTROMAX is indicated for the mobilization of hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis following either autologous or allogeneic stem cell transplantation.
Severe chronic neutropenia (SCN): Chronic administration of NEUTROMAX is indicated for reducing the incidence and duration of sequelae of neutropenia in symptomatic patients with congenital, cyclic and idiopathic neutropenia.
Acute myelogenous leukemia (AML): NEUTROMAX is indicated to reduce the time required for neutrophil recovery and the duration of fever after induction or consolidation chemotherapy treatment of adults with acute myelogenous leukemia.
Continue with Google